|
|
Research Alliances
A key objective of the Avicena Group is to leverage valuable research and development synergies through strategic collaborations and partnerships. Based on this approach, the company has developed key alliances with a number of leading research institutions.
 |
Columbia University
Paul Gordon, M.D. |
 |
Cornell Medical Center
Flint Beal, M.D. |
 |
Carolinas ALS Center
Jeff Rosenfeld, M.D., Ph.D. |
 |
MGH
Merit Cudkowicz, M.D. |
 |
SUNY Upstate Medical University
Jeremy Shefner, M.D., Ph.D. |
 |
Katholieke Universiteit Leuven, Belgium
Peter Hespel, Ph.D. |
|
Massachusetts General Hospital
Steve Hersch, M.D., Ph.D. |
 |
University of Rochester
Karl Kieburtz, M.D. |
 |
University of Cincinnati
Ton DeGrauw, M.D., Ph.D., Joseph Clark, Ph.D. |
 |
McMaster University, Canada
Mark A. Tarnopolsky, M.D., Ph.D., F.R.C.P. (C) |
 |
West Virginia University School of Medicine
Robert Chetlin and Laurie Gutmann, M.D. |
 |
Rancho Los Amigos National Rehabilitation Center
Sophia Chun, M.D., Jacqueline Perry, M.D. |
Furthermore, the Avicena Group has also undertaken a strategic collaboration with Simga Tau Finanziara, a worldwide leader in carnitine and metabolic research. Sigma Tau develops and commercializes products that are designed to treat a variety of rare diseases and medical conditions. Both the Avicena Group and Sigma Tau are focusing on developing orphan drug products and have complimentary technologies targeting energy metabolism.
|
|
| |
|
